Genetic determinants of immunogenicity to factor IX during the treatment of haemophilia B

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2516|21|2|210-218

ISSN： 1351-8216

Source： HAEMOPHILIA, Vol.21, Iss.2, 2015-03, pp. : 210-218

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Role of enhanced half‐life factor VIII and IX in the treatment of haemophilia

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 6, 2015-06 ,pp. : 768-776

John Wiley & Sons Inc

Access to resources Recommend Favorite

Recombinant factor IX (BAX326) in previously treated paediatric patients with haemophilia B: a prospective clinical trial

By  

HAEMOPHILIA, Vol. 21, Iss. 2, 2015-03 ,pp. : 196-203

John Wiley & Sons Inc

Access to resources Recommend Favorite

Age‐related factor IX correction in symptomatic female carriers with haemophilia B Leyden

By  

HAEMOPHILIA, Vol. 21, Iss. 6, 2015-11 ,pp. : e498-e500

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients

By  

HAEMOPHILIA, Vol. 24, Iss. 1, 2018-01 ,pp. : 104-112

John Wiley & Sons Inc

Access to resources Recommend Favorite

Results of a phase I/II open‐label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients

By  

HAEMOPHILIA, Vol. 21, Iss. 6, 2015-11 ,pp. : 784-790

John Wiley & Sons Inc

Access to resources Recommend Favorite